VIPVIZA - VIsualiZation of asymptomatic Atherosclerotic disease for optimum cardiovascular prevention ─ a randomized controlled trial nested in the Västerbotten Intervention Program

The aim of the project is to develop better methods for prevention of cardiovascular diseases (CVD). It is based on the hypothesis that image-based information on subclinical atherosclerosis (i) increases the precision in the assessment of risk of CVD, (ii) improves communication and understanding of the risk, and as a consequence (iii) the motivation for and adherence to evidence-based pharmacological treatment and lifestyle modification will increase. In addition to conventional risk factor assessment and CVD prevention within the framework of Västerbotten Intervention Program. 3500 healthy participants with low/moderate risk of CVD underwent ultrasound examination of the carotid arteries and were randomized to two groups. In the intervention group, the participants and their doctors received pictorial and graphic information in color about the participant’s subclinical atherosclerosis. No information about the ultrasound results was given to the control group. Follow-up after 1, 3 and 6.5 years includes sampling regarding clinical risk factors, blood for biomarker analyses, extensive questionnaires and interviews. At 3 and 6.5 years the ultrasound examination was repeated and all participants and their doctors were informed about the results. The database also includes register data regarding prescriptions of preventive medication, exposure data for air pollutants, data from health examinations within the VIP 10 and 20 years before VIPVIZA, and for men conscription data. After 10 years, registry data on endpoints, CVD morbidity and mortality will be collected. Access to VIPVIZA's data portal and research data from VIPVIZA is possible in collaboration with researchers within the VIPVIZA project. For further information, contact PI Ulf Näslund [e-mail]本项目旨在开发更优化的心血管疾病（cardiovascular diseases, CVD）预防方案。本研究基于以下假说：针对亚临床动脉粥样硬化（subclinical atherosclerosis）的影像相关信息，(i)可提升心血管疾病风险评估的精准度，(ii)可改善风险认知的沟通与理解效果，进而(iii)提升受试者遵循循证药物治疗与生活方式干预的动机与依从性。本研究在西博滕干预项目（Västerbotten Intervention Program，VIP）框架内开展，涵盖常规风险因素评估与心血管疾病预防相关工作。 3500名基线为心血管疾病低/中度风险的健康受试者接受颈动脉超声检查，并被随机分为两组。干预组受试者及其主治医生可获取受试者自身亚临床动脉粥样硬化的彩色图文信息；对照组则不获得任何超声检查结果相关内容。分别在随访1年、3年及6.5年时，研究团队将开展临床风险因素样本采集、生物标志物血液检测、全面问卷调查与访谈调研。 在随访第3年与第6.5年时，研究团队将再次为所有受试者开展颈动脉超声检查，并向所有受试者及其主治医生告知本次检查结果。本项目数据库还涵盖多类登记数据：预防性药物处方数据、空气污染物暴露数据、西博滕干预项目（VIP）在VIPVIZA开展前10年及20年的健康检查数据，以及男性征兵相关数据。 随访满10年后，研究团队将收集终点事件、心血管疾病发病与死亡相关的登记数据。 VIPVIZA项目的数据门户及研究数据的获取需与项目内部研究者合作开展。如需进一步咨询，请联系项目负责人（Principal Investigator, PI）乌尔夫·纳斯隆德（Ulf Näslund），邮箱：[e-mail]